Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:ROKA

(ROKA) (ROKA) Stock Price, News & Analysis

(ROKA) logo

About (ROKA) Stock (NASDAQ:ROKA)

Advanced Chart

Key Stats

Today's Range
$0.65
$0.69
50-Day Range
N/A
52-Week Range
$0.60
$6.20
Volume
242,292 shs
Average Volume
371,374 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Sorrento Tech, Inc., formerly Roka Bioscience, Inc., is a molecular diagnostics company. The Company is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. The Company offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications. The detection of foodborne pathogens is accomplished using culture-based assays, immunochemical-based assays and molecular-based assays. The Company sells its Atlas Detection Assays and related consumable supplies for use with its Atlas instruments. The Company's Atlas instrument is an automated molecular diagnostic testing and a sample-in-result-out instrument that eliminates the need for batch processing and automates all aspects of molecular diagnostic testing on a single, integrated platform.

Receive ROKA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for (ROKA) and its competitors with MarketBeat's FREE daily newsletter.

ROKA Stock News Headlines

Everyone’s watching Nvidia right now. Here’s why I’m excited.
So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal with Saudi Arabia to power its new AI empire 🤯 We’re talking about hundreds of thousands of chips, including their latest Grace Blackwell supercomputer.
See More Headlines

ROKA Stock Analysis - Frequently Asked Questions

(ROKA) (NASDAQ:ROKA) issued its quarterly earnings results on Thursday, May, 11th. The medical research company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.19) by $0.34. The medical research company had revenue of $2.04 million for the quarter.

Based on aggregate information from My MarketBeat watchlists, some other companies that (ROKA) investors own include Credit Suisse High Yield Bond Fund (DHY), Western Asset High Income Fund II (HIX), PIMCO Corporate & Income Opportunity Fund (PTY), ASML (ASML), Corbus Pharmaceuticals (CRBP), STAG Industrial (STAG) and Twitter (TWTR).

Company Calendar

Last Earnings
5/11/2017
Today
5/20/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:ROKA
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Price / Book
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Enter your email address and below to see which companies made the list.

Get This Free Report

This page (NASDAQ:ROKA) was last updated on 5/21/2025 by MarketBeat.com Staff
From Our Partners